Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Cash & Equivalents (2020 - 2025)

iSpecimen has reported Cash & Equivalents over the past 6 years, most recently at $6.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 266.31% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $6.9 million, up 266.31%, while the annual FY2025 figure was $6.9 million, 266.31% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $6.9 million at iSpecimen, up from $2.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $27.7 million in Q4 2021 and troughed at $588775.0 in Q2 2025.
  • A 5-year average of $8.7 million and a median of $2.8 million in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 3886.01% in 2021 and later crashed 91.54% in 2023.
  • Year by year, Cash & Equivalents stood at $27.7 million in 2021, then plummeted by 44.81% to $15.3 million in 2022, then plummeted by 84.69% to $2.3 million in 2023, then dropped by 19.85% to $1.9 million in 2024, then skyrocketed by 266.31% to $6.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for ISPC at $6.9 million in Q4 2025, $2.8 million in Q3 2025, and $588775.0 in Q2 2025.